Onward Therapeutics Reports Updates From the P-I Trial Evaluation of OT-A201 to Treat Solid Tumors
Shots:
- The P-I clinical trial evaluates the safety, tolerability, immunogenicity, preliminary anti-tumor activity of OT-A201 (bispecific Ab) in patients with r/r hematological malignancies or advanced/metastatic solid tumors
- The study is designed to be performed in two parts, the escalation part evaluating OT-A201 as a single agent & the expansion part evaluating the safety & preliminary anti-tumoral activity of OT-A201 as a monotx. or in combination with other therapeutic entity
- As per Onwards’s 2021 agreement with Biomunex, both companies will co-develop OT-A201 until the completion of the P-I study. Moreover, Biomunex has received an undisclosed amount of milestone payment on the first patient dosing in the trial
Ref: Onward Therapeutics | Image: Onward Therapeutics
Related News:- HR Pharmaceuticals and Poiesis Medical Sign a Deal for Dual Balloon Catheter Technology in North America
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
